Moleculin Biotech Inc buy Roth Mkm
Summary
This prediction is currently being closed. Massive losses of -44.59% have been the result for the BUY prediction by Roth_Mkm. Roth_Mkm has a follow-up prediction for Moleculin Biotech Inc where he still thinks Moleculin Biotech Inc is a Buy. Roth_Mkm has 50% into this predictionMoleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Moleculin Biotech Inc | - | - | - |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% |
Comments by Roth_Mkm for this prediction
In the thread Moleculin Biotech Inc diskutieren
In the thread Trading Moleculin Biotech Inc